Eric Venker is listed as a director on 2 SEC Form D filings by 2 issuers between Dec 2021 and Jan 2025: Immunovant, Inc. (New York, NY — pharmaceuticals — 2025; $450M reported sold to 11 investors) and Arbutus Biopharma Corp (Warminster, PA — pharmaceuticals — 2021; $15M reported sold to 1 investors).
What this means 2 separate companies raised money with this person listed as director, over about 4 years. Across those companies the filings report $465M sold in total.
Listed alongside Frank Torti (2 shared filings), Andrew Cheng (1 shared filing), Andrew J. Fromkin (1 shared filing), Atul Pande (1 shared filing), Bill Macias (1 shared filing) and 19 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Eric. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.
What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Eric Venker and found 3 differences, 1 worth asking the sponsor about: Form D filed 1,843 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.